BioCentury | Aug 15, 2020
Product Development

Celltrion launches antigen and serology COVID-19 tests in the U.S., Verily adds capacity with CLIA lab and more

...“Pooled Tech as Way Out of Testing Crunch”).CytoDyn...
...by end of treatment or day 14. CytoDyn...
BioCentury | Aug 5, 2020
Product Development

I-SPY COVID brings new set of targets to master protocols for acute respiratory distress

...for the infection, according to BioCentury’s COVID-19 Resource Center . Leronlimab, a CCR5 antagonist from CytoDyn Inc....
BioCentury | Jul 16, 2020
Regulation

July 15 Quick Takes: Early access in U.K. for Alnylam RNAi; plus Verrica, CytoDyn, J&J and Roche

...film forming solution of cantharidin administered through a single-use applicator. Setback for CytoDyn in HIV CytoDyn Inc....
...topical solution (VP-102) Tecentriq (Brand), RG7446 (Compound #), MPDL3280A (Compound #), atezolizumab (Generic), Tecentriq (Other), Anti-PDL1 (Other) CytoDyn Inc. Johnson...
BioCentury | Apr 14, 2020
Management Tracks

Kelly joins CytoDyn as CMO amid COVID-19 trials; plus Antengene, Genetron, Bolt, BioSpecifics, CMAB and more

...de Ladonchamps, ObsEva’s VP of corporate affairs and finance, will become interim CFO. Robin Sawka, BioCentury Staff CytoDyn Inc. Antengene...
BioCentury | Apr 7, 2020
Product Development

COVID-19 roundup: Inovio starts vaccine trial; plus updates from RedHill, Hope, CytoDyn, Gilead, Takeda, AACR and UNC-Emory

...its previously projected summer trial start date. Outside of vaccines, companies including RedHill, Hope and CytoDyn...
...of infection, including frontline workers, and another to treat hospitalized patients. Trio of CytoDyn trials CytoDyn Inc....
...two patients have been treated with the CCR5 antagonist. As part of an emergency IND, CytoDyn...
BioCentury | Apr 2, 2020
Product Development

COVID-19 roundup: EMA seeks to rein in chloroquine use; plus cash for CEPI, WHO’s SOLIDARITY grows, CytoDyn, EUSA, Chembio, PCR Biosystems and more

...beta; chloroquine; and remdesivir from Gilead Sciences Inc. (NASDAQ:GILD) (see “WHO Launching Master Protocol” ). CytoDyn Inc....
...patients, treated for two weeks, and evaluate mortality at 14 days as the primary endpoint. CytoDyn...
...patients in the New York City area have already received leronlimab under an emergency IND. CytoDyn...
BioCentury | Mar 28, 2020
Product Development

COVID-19 roundup: FDA approves Abbott’s 5-minute test; plus Trump signs stimulus bill, WHO readies master protocol, CytoDyn mAb data and more

...clinical trials and the subsidies provided by governments and charities. Early data for CytoDyn mAb CytoDyn Inc....
...profile in all four patients approached normal levels, with significant decreases in IL-6 and TNFα. CytoDyn...
...in the Phase II trial thus far in a medical center in New York City. CytoDyn...
BioCentury | Mar 19, 2020
Product Development

March 19 COVID-19 Product Development Roundup: Actemra trial begins; plus CytoDyn's leronlimab, a post-exposure prophylaxis trial, and Abbott's EUA

...to treat rheumatoid arthritis. More progress Elsewhere, other organizations reported updates to their COVID-19 programs. CytoDyn Inc....
...granted by FDA. The company has submitted a Phase II trial protocol to the agency. CytoDyn...
...#), R1569 (Compound #), tocilizumab (Generic), RoActemra (Informal), MRA (Informal), Actemra (Informal) leronlimab (PRO 140) HCQ, hydroxychloroquine Roche Genentech Inc. CytoDyn Inc. Abbott...
BioCentury | Mar 13, 2020
Management Tracks

Camerini steps down as Cosmo CSO; plus CytoDyn, G1 Therapeutics, Flexion and Clearside

...come out of retirement to serve as interim CSO until a permanent successor is found. CytoDyn Inc....
...as interim CEO. Targets CCR5 (CD195) - CC chemokine receptor 5 Robin Sawka, BioCentury Staff Cosmo Pharmaceuticals N.V. CytoDyn Inc. G1...
BioCentury | Aug 9, 2019
Preclinical News

Aug. 8 Preclinical Quick Takes: Mayo Clinic assay for residual disease; plus camouflage for bacterial agents, Elicio's KRAS vaccine and more

...toxicity and efficacy screening (see "Tara’s Beating Heart" ). Anti-CCR5 mAb blocks colorectal cancer growth CytoDyn Inc....
...PRO 140), suppressed the growth of tumors expressing CCR5 in mouse models of colorectal cancer. CytoDyn...
...Phosphoinositide 3-kinase catalytic subunit α polypeptide Hongjiang Li and Sandi Wong, Staff Writers leronlimab (PRO 140) NDV-3A, NDV-3 Cleveland Clinic CytoDyn Inc. Elicio...
Items per page:
1 - 10 of 59
BioCentury | Aug 15, 2020
Product Development

Celltrion launches antigen and serology COVID-19 tests in the U.S., Verily adds capacity with CLIA lab and more

...“Pooled Tech as Way Out of Testing Crunch”).CytoDyn...
...by end of treatment or day 14. CytoDyn...
BioCentury | Aug 5, 2020
Product Development

I-SPY COVID brings new set of targets to master protocols for acute respiratory distress

...for the infection, according to BioCentury’s COVID-19 Resource Center . Leronlimab, a CCR5 antagonist from CytoDyn Inc....
BioCentury | Jul 16, 2020
Regulation

July 15 Quick Takes: Early access in U.K. for Alnylam RNAi; plus Verrica, CytoDyn, J&J and Roche

...film forming solution of cantharidin administered through a single-use applicator. Setback for CytoDyn in HIV CytoDyn Inc....
...topical solution (VP-102) Tecentriq (Brand), RG7446 (Compound #), MPDL3280A (Compound #), atezolizumab (Generic), Tecentriq (Other), Anti-PDL1 (Other) CytoDyn Inc. Johnson...
BioCentury | Apr 14, 2020
Management Tracks

Kelly joins CytoDyn as CMO amid COVID-19 trials; plus Antengene, Genetron, Bolt, BioSpecifics, CMAB and more

...de Ladonchamps, ObsEva’s VP of corporate affairs and finance, will become interim CFO. Robin Sawka, BioCentury Staff CytoDyn Inc. Antengene...
BioCentury | Apr 7, 2020
Product Development

COVID-19 roundup: Inovio starts vaccine trial; plus updates from RedHill, Hope, CytoDyn, Gilead, Takeda, AACR and UNC-Emory

...its previously projected summer trial start date. Outside of vaccines, companies including RedHill, Hope and CytoDyn...
...of infection, including frontline workers, and another to treat hospitalized patients. Trio of CytoDyn trials CytoDyn Inc....
...two patients have been treated with the CCR5 antagonist. As part of an emergency IND, CytoDyn...
BioCentury | Apr 2, 2020
Product Development

COVID-19 roundup: EMA seeks to rein in chloroquine use; plus cash for CEPI, WHO’s SOLIDARITY grows, CytoDyn, EUSA, Chembio, PCR Biosystems and more

...beta; chloroquine; and remdesivir from Gilead Sciences Inc. (NASDAQ:GILD) (see “WHO Launching Master Protocol” ). CytoDyn Inc....
...patients, treated for two weeks, and evaluate mortality at 14 days as the primary endpoint. CytoDyn...
...patients in the New York City area have already received leronlimab under an emergency IND. CytoDyn...
BioCentury | Mar 28, 2020
Product Development

COVID-19 roundup: FDA approves Abbott’s 5-minute test; plus Trump signs stimulus bill, WHO readies master protocol, CytoDyn mAb data and more

...clinical trials and the subsidies provided by governments and charities. Early data for CytoDyn mAb CytoDyn Inc....
...profile in all four patients approached normal levels, with significant decreases in IL-6 and TNFα. CytoDyn...
...in the Phase II trial thus far in a medical center in New York City. CytoDyn...
BioCentury | Mar 19, 2020
Product Development

March 19 COVID-19 Product Development Roundup: Actemra trial begins; plus CytoDyn's leronlimab, a post-exposure prophylaxis trial, and Abbott's EUA

...to treat rheumatoid arthritis. More progress Elsewhere, other organizations reported updates to their COVID-19 programs. CytoDyn Inc....
...granted by FDA. The company has submitted a Phase II trial protocol to the agency. CytoDyn...
...#), R1569 (Compound #), tocilizumab (Generic), RoActemra (Informal), MRA (Informal), Actemra (Informal) leronlimab (PRO 140) HCQ, hydroxychloroquine Roche Genentech Inc. CytoDyn Inc. Abbott...
BioCentury | Mar 13, 2020
Management Tracks

Camerini steps down as Cosmo CSO; plus CytoDyn, G1 Therapeutics, Flexion and Clearside

...come out of retirement to serve as interim CSO until a permanent successor is found. CytoDyn Inc....
...as interim CEO. Targets CCR5 (CD195) - CC chemokine receptor 5 Robin Sawka, BioCentury Staff Cosmo Pharmaceuticals N.V. CytoDyn Inc. G1...
BioCentury | Aug 9, 2019
Preclinical News

Aug. 8 Preclinical Quick Takes: Mayo Clinic assay for residual disease; plus camouflage for bacterial agents, Elicio's KRAS vaccine and more

...toxicity and efficacy screening (see "Tara’s Beating Heart" ). Anti-CCR5 mAb blocks colorectal cancer growth CytoDyn Inc....
...PRO 140), suppressed the growth of tumors expressing CCR5 in mouse models of colorectal cancer. CytoDyn...
...Phosphoinositide 3-kinase catalytic subunit α polypeptide Hongjiang Li and Sandi Wong, Staff Writers leronlimab (PRO 140) NDV-3A, NDV-3 Cleveland Clinic CytoDyn Inc. Elicio...
Items per page:
1 - 10 of 59